\
&
Contact us
\
&
Contact us
Published on | 1 hour ago
ProgrammesThe Climate KIC of the European Institute for Innovation and Technology (EIT) opens applications for 2026 Climathon organisers of events that encourage systemic climate action through local challenges.
Climathon events are designed to unite citizens in addressing local climate challenges, with formats that can be in-person, hybrid, or virtual, typically lasting between 12 to 48 hours. Since its inception in 2015, Climathon has seen the participation of around 600 organisers and over 30,000 individuals globally.
Any organisation is welcome to apply to become a Climathon Organiser, including SMEs, universities, city councils, and NGOs. Organisers will oversee the local implementation of the event, with support provided by Climate KIC. A Climathon Organiser licence grants access to resources such as training webinars, a Climathon Playbook, and networking opportunities with fellow organisers. Please note that a membership is necessary to get access to our resources and trainings.
Organisations are encouraged to apply here for the Climathon Organiser licence before the 31 March 2026 deadline.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
